Skip to content
Inciteful Med

The First Step: Induction and Transplant

Last updated:

The standard initial treatment for eligible Multiple Myeloma patients involves induction therapy followed by an autologous stem cell transplant. Induction uses drug combinations like VRd or D-VRd to reduce cancer cells, while the transplant resets the bone marrow using the patient's own stem cells.

Key Takeaways

  • • The standard treatment path for most new patients is Induction followed by Transplant and Maintenance.
  • • Newer 'quadruplet' induction therapies (D-VRd) include Daratumumab and show deeper responses than the standard VRd.
  • • Autologous transplants use your own stem cells, making them safer than donor transplants.
  • • Transplant eligibility is determined by biological fitness and frailty, not just age.
  • • Patients typically recover from transplant in about two weeks, often requiring caregiver support.

For most newly diagnosed patients, the standard treatment path is: Induction →\rightarrow Transplant →\rightarrow Maintenance [1][2].

Phase 1: Induction Therapy

The goal is to kill as much cancer as possible quickly [2].

  • Standard (VRd): Velcade (Bortezomib) + Revlimid (Lenalidomide) + dexamethasone [3].
  • New Standard (D-VRd): Adding Daratumumab (Darzalex) to VRd. Clinical trials show this “quadruplet” leads to significantly deeper responses [4][5].

Phase 2: Autologous Stem Cell Transplant (ASCT)

This is a “reset” for your bone marrow.

  • “Autologous”: Uses your own stem cells. No donor needed. It is safer than donor transplants [2].
  • Eligibility: Based on “biological fitness” and frailty scores, not just age. Many fit patients in their 70s undergo ASCT [6][7].

The Process

  1. Mobilization: You get shots to move stem cells into your blood.
  2. Collection: A machine collects the cells (like giving blood). This is usually outpatient [8].
  3. High-Dose Chemo: You receive Melphalan. It kills the cancer but also the marrow [9].
  4. Re-infusion: Your frozen cells are given back to you to “rescue” your marrow [10].
  5. Recovery: 2 weeks of low blood counts. You may be in the hospital or monitored closely at home [11].

Side Effects

  • Dexamethasone: Insomnia, irritability, high blood sugar [12].
  • Velcade: Neuropathy (tingling hands/feet). Tell your doctor immediately if this starts! [13].
  • Revlimid: Blood clot risk. You will likely take aspirin or a blood thinner [14].
  • Melphalan: Mouth sores, hair loss, fatigue [15].

Frequently Asked Questions

What is induction therapy for multiple myeloma?
Induction therapy is the first phase of treatment aimed at killing as much cancer as possible quickly. The standard regimen is often VRd (Velcade, Revlimid, and dexamethasone), while a newer standard called D-VRd adds a fourth drug, Daratumumab, for deeper responses.
Am I too old for a stem cell transplant?
Eligibility for a transplant is based on your biological fitness and frailty scores rather than your chronological age. Many medically fit patients in their 70s successfully undergo autologous stem cell transplants.
Do I need a donor for my stem cell transplant?
An autologous stem cell transplant (ASCT) uses your own stem cells, which means no donor is needed. This approach is generally safer than transplants using donor cells because it avoids the risk of your body rejecting the new cells.
What are the steps of the transplant process?
The process typically involves mobilization (moving cells to blood), collection (filtering cells out), high-dose chemotherapy with Melphalan to treat the cancer, re-infusion of your cells to rescue the marrow, and a recovery period of about two weeks.
What side effects should I expect from induction and transplant drugs?
Common side effects include neuropathy (tingling) from Velcade, insomnia or irritability from dexamethasone, and blood clot risks from Revlimid. The transplant drug Melphalan may cause mouth sores, hair loss, and fatigue.

Questions for Your Doctor

  • • Am I a candidate for an autologous stem cell transplant (ASCT) based on my fitness and frailty score?
  • • Should we use the four-drug 'D-VRd' regimen (adding Daratumumab) for my induction?
  • • What are the side effects of high-dose Melphalan I should prepare for?
  • • What is the plan for stem cell mobilization—will I do this outpatient?
  • • How will we manage neuropathy from Velcade?

Questions for You

  • • Do I have a caregiver who can help me during the 2-3 week transplant recovery?
  • • Am I prepared for the 'steroid beast' (insomnia/irritability) from Dexamethasone?
  • • Have I asked about freezing my stem cells even if I don't want a transplant right away?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Deepening Responses after Upfront Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction Therapy.

    Ebraheem M, Kumar SK, Dispenzieri A, et al.

    Transplantation and cellular therapy 2022; (28(11)):760.e1-760.e5 doi:10.1016/j.jtct.2022.07.030.

    PMID: 35940527
  2. 2

    Recommend upfront consolidation with high-dose melphalan and autologous stem cell support.

    Shah GL, Giralt SA

    Seminars in oncology 2016; (43(6)):707-708 doi:10.1053/j.seminoncol.2016.11.007.

    PMID: 28061992
  3. 3

    Evolution of Treatment Paradigms in Newly Diagnosed Multiple Myeloma.

    Elnair RA, Holstein SA

    Drugs 2021; (81(7)):825-840 doi:10.1007/s40265-021-01514-0.

    PMID: 33871818
  4. 4

    Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

    Sonneveld P, Dimopoulos MA, Boccadoro M, et al.

    The New England journal of medicine 2024; (390(4)):301-313 doi:10.1056/NEJMoa2312054.

    PMID: 38084760
  5. 5

    Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial.

    Voorhees PM, Sborov DW, Laubach J, et al.

    The Lancet. Haematology 2023; (10(10)):e825-e837 doi:10.1016/S2352-3026(23)00217-X.

    PMID: 37708911
  6. 6

    Upfront autologous stem cell transplantation for newly diagnosed elderly multiple myeloma patients: a prospective multicenter study.

    Garderet L, Beohou E, Caillot D, et al.

    Haematologica 2016; (101(11)):1390-1397 doi:10.3324/haematol.2016.150334.

    PMID: 27612987
  7. 7

    Autologous stem cell transplantation in elderly multiple myeloma patients aged ≥65 years: a two-centre Australian experience.

    Er J, Routledge D, Hempton J, et al.

    Internal medicine journal 2021; (51(2)):280-283 doi:10.1111/imj.15182.

    PMID: 33631863
  8. 8

    Efficacy and safety of etoposide + cytarabine + pegfilgrastim mobilization regimen versus G-CSF mobilization regimen alone for hematopoietic stem cell mobilization in patients with multiple myeloma and lymphoma.

    Xu S, Cheng Y, Pei R, et al.

    Cytotherapy 2025; (27(8)):973-979 doi:10.1016/j.jcyt.2025.05.012.

    PMID: 40679461
  9. 9

    Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction: A Systematic Review and Meta-analysis.

    Dhakal B, Szabo A, Chhabra S, et al.

    JAMA oncology 2018; (4(3)):343-350 doi:10.1001/jamaoncol.2017.4600.

    PMID: 29302684
  10. 10

    [Application of Conditioning Regimen with Busulfan and Cyclophosphamide in Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma].

    Xu Y, Zhou J, Ma L, et al.

    Zhongguo shi yan xue ye xue za zhi 2021; (29(6)):1831-1836 doi:10.19746/j.cnki.issn.1009-2137.2021.06.024.

    PMID: 34893119
  11. 11

    Phagocyte function decreases after high-dose treatment with melphalan and autologous stem cell transplantation in patients with multiple myeloma.

    Wichert S, Pettersson Å, Hellmark T, et al.

    Experimental hematology 2016; (44(5)):342-351.e5.

    PMID: 26774385
  12. 12

    Pulmonary arterial hypertension in a patient with multiple myeloma during carfilzomib treatment: in search of better management.

    Rago A, Siniscalchi A, Tordi A, et al.

    Tumori 2021; (107(6)):NP37-NP40 doi:10.1177/0300891621990427.

    PMID: 33525991
  13. 13

    High efficacy and safety of VTD as an induction protocol in patients with newly diagnosed multiple myeloma eligible for high dose therapy and autologous stem cell transplantation: A report of the Polish Myeloma Study Group.

    Hus I, Mańko J, Jawniak D, et al.

    Oncology letters 2019; (18(6)):5811-5820 doi:10.3892/ol.2019.10929.

    PMID: 31788054
  14. 14

    Lenalidomide-induced eosinophilic pneumonia.

    Toma A, Rapoport AP, Burke A, Sachdeva A

    Respirology case reports 2017; (5(4)):e00233 doi:10.1002/rcr2.233.

    PMID: 28451433
  15. 15

    Lower glomerular filtration rate predicts increased hepatic and mucosal toxicity in myeloma patients treated with high-dose melphalan.

    Tamaki M, Nakasone H, Gomyo A, et al.

    International journal of hematology 2018; (108(4)):423-431 doi:10.1007/s12185-018-2507-2.

    PMID: 30039440

This guide explains standard induction and transplant protocols for educational purposes. Treatment plans vary by patient, so always consult your oncologist for advice specific to your health profile.

Stay up to date

Get notified when new research about Multiple Myeloma is published.

No spam. Unsubscribe anytime.